201 related articles for article (PubMed ID: 26649645)
1. Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort.
Obi N; Heinz J; Seibold P; Vrieling A; Rudolph A; Chang-Claude J; Berger J; Flesch-Janys D
Int J Cancer; 2016 May; 138(9):2098-108. PubMed ID: 26649645
[TBL] [Abstract][Full Text] [Related]
2. Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
Fornili M; Perduca V; Fournier A; Jérolon A; Boutron-Ruault MC; Maskarinec G; Severi G; Baglietto L
Breast Cancer Res; 2021 Apr; 23(1):47. PubMed ID: 33865453
[TBL] [Abstract][Full Text] [Related]
3. Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study.
Salagame U; Banks E; Sitas F; Canfell K
Int J Cancer; 2016 Apr; 138(8):1905-14. PubMed ID: 26599391
[TBL] [Abstract][Full Text] [Related]
4. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
5. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study.
Rosenberg LU; Granath F; Dickman PW; Einarsdóttir K; Wedrén S; Persson I; Hall P
Breast Cancer Res; 2008; 10(5):R78. PubMed ID: 18803850
[TBL] [Abstract][Full Text] [Related]
6. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
Cadeau C; Fournier A; Mesrine S; Clavel-Chapelon F; Fagherazzi G; Boutron-Ruault MC
Int J Cancer; 2016 Nov; 139(10):2193-200. PubMed ID: 27451078
[TBL] [Abstract][Full Text] [Related]
7. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.
Cold S; Cold F; Jensen MB; Cronin-Fenton D; Christiansen P; Ejlertsen B
J Natl Cancer Inst; 2022 Oct; 114(10):1347-1354. PubMed ID: 35854422
[TBL] [Abstract][Full Text] [Related]
8. Prediagnostic use of estrogen-only therapy is associated with improved colorectal cancer survival in menopausal women: a Swedish population-based cohort study.
Simin J; Liu Q; Wang X; Fall K; Williams C; Callens S; Engstrand L; Brusselaers N
Acta Oncol; 2021 Jul; 60(7):881-887. PubMed ID: 33861686
[TBL] [Abstract][Full Text] [Related]
9. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials.
Greiser CM; Greiser EM; Dören M
Hum Reprod Update; 2005; 11(6):561-73. PubMed ID: 16150812
[TBL] [Abstract][Full Text] [Related]
10. Association of pre-diagnosis physical activity with recurrence and mortality among women with breast cancer.
Schmidt ME; Chang-Claude J; Vrieling A; Seibold P; Heinz J; Obi N; Flesch-Janys D; Steindorf K
Int J Cancer; 2013 Sep; 133(6):1431-40. PubMed ID: 23444048
[TBL] [Abstract][Full Text] [Related]
11. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
Jones ME; Schoemaker MJ; Wright L; McFadden E; Griffin J; Thomas D; Hemming J; Wright K; Ashworth A; Swerdlow AJ
Br J Cancer; 2016 Aug; 115(5):607-15. PubMed ID: 27467055
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
13. Female Estrogen-Related Factors and Incidence of Basal Cell Carcinoma in a Nationwide US Cohort.
Cahoon EK; Kitahara CM; Ntowe E; Bowen EM; Doody MM; Alexander BH; Lee T; Little MP; Linet MS; Freedman DM
J Clin Oncol; 2015 Dec; 33(34):4058-65. PubMed ID: 26527779
[TBL] [Abstract][Full Text] [Related]
14. Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project.
Wang T; Bradshaw PT; Moorman PG; Nyante SJ; Nichols HB; Shantakumar S; Parada H; Khankari NK; Terry MB; Teitelbaum SL; Neugut AI; Gammon MD
Int J Cancer; 2020 Dec; 147(12):3404-3415. PubMed ID: 32588422
[TBL] [Abstract][Full Text] [Related]
15. Associations between diabetes medication use and risk of second breast cancer events and mortality.
Calip GS; Yu O; Hoskins KF; Boudreau DM
Cancer Causes Control; 2015 Aug; 26(8):1065-77. PubMed ID: 25956271
[TBL] [Abstract][Full Text] [Related]
16. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition.
Bakken K; Fournier A; Lund E; Waaseth M; Dumeaux V; Clavel-Chapelon F; Fabre A; Hémon B; Rinaldi S; Chajes V; Slimani N; Allen NE; Reeves GK; Bingham S; Khaw KT; Olsen A; Tjønneland A; Rodriguez L; Sánchez MJ; Etxezarreta PA; Ardanaz E; Tormo MJ; Peeters PH; van Gils CH; Steffen A; Schulz M; Chang-Claude J; Kaaks R; Tumino R; Gallo V; Norat T; Riboli E; Panico S; Masala G; González CA; Berrino F
Int J Cancer; 2011 Jan; 128(1):144-56. PubMed ID: 20232395
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of hormone therapy among women with hysterectomy/oophorectomy.
Chen L; Mishra GD; Dobson AJ; Wilson LF; Jones MA
Hum Reprod; 2017 Apr; 32(4):885-892. PubMed ID: 28184451
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea-based cohort study.
Yuk JS; Kim T; Cho H; Gwak G
Eur J Endocrinol; 2024 Jan; 190(1):1-11. PubMed ID: 38128117
[TBL] [Abstract][Full Text] [Related]
19. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
20. Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort.
Nickels S; Vrieling A; Seibold P; Heinz J; Obi N; Flesch-Janys D; Chang-Claude J
PLoS One; 2013; 8(9):e75088. PubMed ID: 24086446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
